Ro vs Fridays: Which GLP-1 Telehealth Platform Suits You?

Last reviewed: May 15, 2026

Last updated: May 15, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Ro and Fridays represent two major telehealth platforms competing for GLP-1 prescription volume. Ro operates as a full-service digital pharmacy connecting patients to prescribers; Fridays focuses specifically on weight-loss peptides through a subscription model. Both enable remote medical evaluation, but their clinical protocols, drug inventories, and cost structures diverge significantly.

Choosing between Ro and Fridays requires understanding not just their features, but how telehealth evaluation itself differs from in-person assessment. This matters because GLP-1 therapy involves metabolic, cardiovascular, and gastrointestinal considerations that deserve thorough screening. PlexusDx takes a precision-wellness approach by combining compounded peptide options with optional genetic testing to contextualize individual peptide-pathway predispositions—supporting a more informed conversation with your provider.

Ro: Multi-Drug Platform Model and Clinical Workflow

Ro operates as a digital health company offering multiple prescription categories, including GLP-1 drugs for both diabetes and weight management. Patients complete an online questionnaire, speak with a Ro-affiliated physician via video, and receive prescriptions dispensed through Ro's pharmacy network. Ro stocks both branded options (Ozempic, Wegovy, Mounjaro) and occasionally partners with compounding pharmacies for cost-effective alternatives.

Ro's clinical evaluation focuses on metabolic history, cardiovascular risk, and baseline kidney function. The platform uses standardized assessment templates aligned with FDA-approved labeling. Typical costs range from $199–$399 monthly depending on drug choice. Ro's strength lies in its broad drug inventory and established insurance partnerships, though wait times for initial consultations can extend 1–2 weeks during high-demand periods.

Fridays: Specialized GLP-1 Subscription Service

Fridays targets weight-loss seekers specifically, positioning itself as a dedicated GLP-1 subscription service rather than a general telehealth marketplace. The platform offers branded semaglutide (Wegovy equivalent) and tirzepatide (Mounjaro equivalent) through a fixed monthly subscription starting around $99 (lower tier) up to $399 (premium). Fridays emphasizes simplicity: no fragmented pharmacy network, no insurance haggling.

Fridays' medical evaluation includes a questionnaire, video visit with a provider, and ongoing clinical monitoring through the app. The platform leverages lifestyle coaching and progress tracking as differentiators. Fridays' subscription model appeals to patients seeking predictable costs and integrated support, but inventory is narrower than Ro. Both platforms rely on branded GLP-1 drugs, meaning pricing reflects manufacturer costs and market demand.

Clinical Evaluation Depth: Biomarkers, Baseline Labs, and Provider Decision-Making

Both Ro and Fridays require baseline health information, but neither mandates bloodwork before the initial prescription. Fridays requests metabolic history and cardiovascular screening via questionnaire; Ro performs a similar assessment. Neither platform emphasizes genetic predisposition testing. For patients with complicated medical histories—prior pancreatitis, severe kidney disease, active thyroid cancer—in-person medical evaluation with labs may be safer than telehealth-only assessment.

The clinical reality is that GLP-1 therapy involves personalized considerations: gastrointestinal tolerance varies widely between individuals, thyroid-related adverse events require monitoring, and medication interactions depend on each patient's full pharmaceutical profile. A thorough telehealth visit can address these, but standardized questionnaires may miss nuances. PlexusDx supports providers by offering an optional Precision Peptide Genetic Test that reveals predispositions in peptide-pathway genes (GLP1R, GIPR, FTO, MC4R variants), allowing more targeted conversations about individual response risk and dose optimization without guaranteeing exact outcomes.

Pricing, Drug Access, and Pharmacy Model Comparison

The cost and drug-access landscape differs between these platforms. Ro offers flexibility: patients can switch between branded Wegovy, Ozempic, Mounjaro, and sometimes compounded alternatives mid-treatment, accessing whatever their insurance covers or cash-pay inventory permits. Fridays locks patients into a monthly subscription tier, which simplifies budgeting but reduces mid-contract flexibility.

Factor	Ro	Fridays	PlexusDx
Drug Inventory	Branded + select compounded	Branded only (Wegovy, Mounjaro)	Compounded GLP-1 (503A pharmacy)
Monthly Cost Range	$199–$399	$99–$399 subscription	$129–$309 compounded
Pharmacy Model	Multi-network + Ro pharmacy	Fridays-branded fulfillment	Licensed 503A compounders
Initial Consultation	Telehealth video + questionnaire	Telehealth video + questionnaire	Provider coordination via PlexusDx
Optional Genetic Testing	Not offered	Not offered	Precision Peptide Test ($99–$298)

Safety Considerations and Medical Eligibility Screening

Both Ro and Fridays implement safety protocols: contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, diabetic retinopathy, and severe kidney disease. Telehealth providers verify these via questionnaire, but patients must answer honestly and completely. If you have complex comorbidities or prior adverse reactions to similar drugs, in-person evaluation with a weight-medicine specialist may be prudent before initiating therapy.

Fridays and Ro both require ongoing provider communication if side effects emerge—nausea, constipation, pancreatitis symptoms, or thyroid concerns. Neither platform replaces emergent medical care. Patients on either platform should understand that compounded peptides carry additional considerations: compounded semaglutide and tirzepatide are not FDA-approved drugs, meaning they lack branded stability guarantees and rely on 503A pharmacy quality standards. PlexusDx exclusively partners with licensed 503A pharmacies to maintain strict compounding oversight, though compounded and branded GLP-1 medications carry similar clinical risks and benefits when dosed appropriately.

How PlexusDx Supports a More Personalized Approach

Understanding your individual peptide-pathway genetics may support a more informed prescription conversation. Genetic variants in the GLP1R gene (rs6923761) and GIPR gene (rs1800437) influence how your body responds to GLP-1 receptor agonists. Variants in FTO (rs9939609) and MC4R (rs17782313) relate to baseline metabolic and appetite regulation. These predispositions do not predict your exact response to semaglutide or tirzepatide, but they may help provide context for provider decision-making about dose escalation, medication selection, or potential side-effect risk.

PlexusDx offers a Precision Peptide Genetic Test ($99 as an add-on or $298 standalone) that reveals these peptide-pathway predispositions without being a pharmacogenomic test. When ordered alongside a compounded GLP-1 prescription, the genetic insights can support a more personalized conversation with your healthcare provider about dosing strategy, drug selection, and monitoring priorities. The test interprets results alongside clinical biomarkers—fasting glucose, kidney function, pancreatic history—to contextualize your individual peptide-therapy profile.

Whether you choose Ro, Fridays, or explore compounded options through PlexusDx, involving your primary-care provider or endocrinologist in the decision strengthens safety and outcomes. Genetic predispositions, current medications, and prior GLP-1 tolerance should all inform your provider's recommendation. PlexusDx facilitates that conversation by offering both compounded peptides and genetic context—allowing your provider to tailor therapy rather than defaulting to a one-size-fits-all protocol.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

What is the key difference between Ro and Fridays for GLP-1 access?

Ro is a multi-category telehealth pharmacy offering various GLP-1 brands and sometimes compounded options; Fridays is a specialized GLP-1 subscription service focused on weight loss with a fixed monthly model. Ro provides more drug flexibility; Fridays emphasizes simplicity and integrated coaching.

Does Fridays require baseline bloodwork before prescribing?

Fridays requires health history and cardiovascular screening via questionnaire but does not mandate lab work before initial prescription. A telehealth provider reviews your responses and decides whether labs are necessary based on your health profile.

Can I switch between Ro and Fridays mid-treatment?

Yes, you can transfer your prescription or start fresh with either platform at any time. However, switching interrupts continuity; coordinating with your new provider about your prior dose, side effects, and goals minimizes transition risk.

How does PlexusDx compounded GLP-1 pricing compare to Ro and Fridays?

PlexusDx compounded semaglutide ranges $149/mo and tirzepatide $249/mo, often undercutting Ro and Fridays when insurance doesn't cover branded options. All three require provider evaluation; PlexusDx adds optional genetic testing for $99–$298.

What does the Precision Peptide Genetic Test reveal?

It identifies predispositions in peptide-pathway genes (GLP1R, GIPR, FTO, MC4R) that may contextualize your GLP-1 response. These are not guarantees of outcome but can support your provider's dosing and drug-selection conversation when combined with clinical biomarkers.

Are compounded GLP-1 drugs from PlexusDx as safe as Ro's or Fridays' branded options?

Compounded GLP-1 medications from licensed 503A pharmacies carry similar clinical efficacy and safety profiles as branded drugs when dosed identically. PlexusDx exclusively uses 503A pharmacies for oversight. Both modalities require appropriate medical screening and provider monitoring.

Ro vs Fridays: Telehealth Platform Selection for GLP-1 Peptide Therapy

Ro and Fridays are telehealth platforms offering GLP-1 prescriptions through remote medical evaluation, but they differ in drug selection, pricing models, and clinical assessment depth.

GLP-1 weight loss starts at $129/mo Provider-reviewed options. No membership fees.

See if you qualify →